Latest Sciele Pharma Stories
Sciele Pharma, which specializes in sales, marketing and development of branded prescription products, has completed a pivotal Phase III program to support an NDA filing for glycopyrrolate liquid.
Sciele Pharma and Addrenex Pharmaceuticals have announced that the preliminary analysis of the Phase III clinical study investigating the use of Clonicel for the treatment of attention deficit hyperactivity disorder has shown statistically significant improvement over placebo.
Sciele Pharma, which develops branded prescription products, has announced that the FDA has issued an approvable letter for the head lice treatment. Sciele Pharma is working closely with Summers Laboratories and the FDA to provide additional information that was requested.
DURHAM, N.C., July 1 /PRNewswire/ -- Two years after Addrenex Pharmaceuticals set it sights on building a new class of drugs to regulate "adrenergic excess," the small Durham company has signed its second major deal with Sciele Pharma, this time to co-develop a new compound for hypertension and other potential indications.